Ted W. Love, MD, President and CEO of Global Blood Therapeutics (GBT), says the efficacy of Oxbryta™ and its pricing below the average for orphan drugs are among justifications for its $125,000-a-year cost, rejecting criticism over the drug’s price from the nonprofit Institute for Clinical and Economic Review (ICER). [Global Blood Therapeutics via YouTube]
Ted W. Love, MD, president and CEO of Global Blood Therapeutics (GBT), defended the list price of his company’s recently-approved sickle-cell disease drug Oxbryta™ (voxelotor) before an audience of investors in New York . . .